Beckley Psytech has initiated a Phase IIa study of its 5-MeO-DMT candidate – BPL-003 – for Alcohol Use Disorder (AUD), which will take place at King’s...
While psychedelic research has, to date, largely focused on mathematical modelling and resting-state neuroimaging, cognitive neuroscientists are bringing new rigour to the field through the use...
A group of 13 individuals have become the first people to be licensed to facilitate psilocybin experiences in the United States outside of clinical trials in...
Researchers from the Universidade de São Paulo (USP) and ICEERS have found that ayahuasca may modulate neural networks, and suggest that more research is needed to...
Psyched Wellness has carried out a neurobehavioral study evaluating the safety and efficacy of its Amanita Muscaria extract – AME-1.
Mind Medicine Australia has provided funding for two studies that will be investigating the use of psilocybin and MDMA.
Detailed brain imaging data from 20 healthy volunteers has revealed how DMT increased connectivity across the brain, with more communication between different areas and systems.
Psychedelic-assisted therapies could hit UK markets sooner than expected – and sooner than may happen in Europe – under a new government funding plan for innovative...
When psychedelic therapies begin to gain regulatory approval, they will need to be incorporated into the medical billing and coding system in a way that ensures...
Psychedelic substances, such as LSD and psilocybin, are known for their effects on the brain that can produce profound changes in perception, mood and consciousness.